Key Insights

Highlights

Success Rate

96% trial completion (above average)

Published Results

13 trials with published results (36%)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 17/100

Termination Rate

2.8%

1 terminated out of 36 trials

Success Rate

95.8%

+9.3% vs benchmark

Late-Stage Pipeline

39%

14 trials in Phase 3/4

Results Transparency

57%

13 of 23 completed with results

Key Signals

13 with results96% success

Data Visualizations

Phase Distribution

29Total
Not Applicable (2)
Early P 1 (1)
P 2 (12)
P 3 (14)

Trial Status

Completed23
Recruiting5
Withdrawn3
Not Yet Recruiting2
Active Not Recruiting1
Terminated1

Trial Success Rate

95.8%

Benchmark: 86.5%

Based on 23 completed trials

Clinical Trials (36)

Showing 20 of 20 trials
NCT07037771Phase 3RecruitingPrimary

A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)

NCT07473843Phase 3Not Yet RecruitingPrimary

Study of Zodasiran in Adolescent Participants With Homozygous Familial Hypercholesterolemia

NCT04815005RecruitingPrimary

HoFH, the International Clinical Collaborators Registry

NCT06723652Phase 3CompletedPrimary

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia

NCT05217667Phase 2Active Not RecruitingPrimary

Study of ARO-ANG3 in Participants With Homozygous Familial Hypercholesterolemia (HOFH)

NCT06009393Phase 2CompletedPrimary

Evaluate the Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia

NCT07133815Phase 2Not Yet RecruitingPrimary

Evaluate the Long-term Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia

NCT01109368RecruitingPrimary

The Rogosin Institute Homozygous Familial Hypercholesterolemia Repository

NCT03409744Phase 3CompletedPrimary

Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia

NCT05611528Phase 3CompletedPrimary

Safety and Effectiveness of Evinacumab for the Treatment of Homozygous Familial Hypercholesterolemia

NCT06125847Early Phase 1RecruitingPrimary

NGGT006 Gene Therapy for Homozygous Familial Hypercholesterolemia

NCT04233918Phase 3CompletedPrimary

Evaluate the Efficacy and Safety of Evinacumab in Pediatric Patients With Homozygous Familial Hypercholesterolemia

NCT02135705RecruitingPrimary

LOWER: Lomitapide Observational Worldwide Evaluation Registry

NCT03814187Phase 3Completed

Trial to Assess the Effect of Long Term Dosing of Inclisiran in Subjects With High CV Risk and Elevated LDL-C

NCT04031742Phase 2CompletedPrimary

A Study to Evaluate Safety and Efficacy of IBI306, a PCSK9 Monoclonal Antibody in Chinese Subjects With Homozygous Familial Hypercholesterolemia

NCT04034485Phase 3CompletedPrimary

Phase 3 Study to Evaluate the Efficacy and Safety of LIB003 With Evolocumab in HoFH

NCT03933293Phase 2CompletedPrimary

A Study to Evaluate the Safety and Efficacy of the PCSK9 Inhibitor AK102 in Patients With HoFH

NCT03851705Phase 3CompletedPrimary

A Study of Inclisiran in Participants With Homozygous Familial Hypercholesterolemia (HoFH)

NCT00704535Completed

Evaluation of the Safety, Tolerability and Efficacy of Ezetimibe on a Select Population of Filipinos With Hypercholesterolemia (Study P04748)(COMPLETED)

NCT03156621Phase 3CompletedPrimary

Study in Participants With Homozygous Familial Hypercholesterolemia (HoFH)

Scroll to load more

Research Network

Activity Timeline